Stem Cell Company AmStem Appoints Neuro-Oncology Expert Dr. Michael J. Glantz to Scientific and Medical Board of Advisors

Stem Cell Company AmStem Appoints Neuro-Oncology Expert Dr. Michael J. Glantz to Scientific and Medical Board of Advisors


SAN FRANCISCO & SEOUL, South Korea--(BUSINESS WIRE)--Oct 5, 2010 - AmStem Corporation (Pink Sheets: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today the appointment of Dr. Michael J. Glantz, M.D. to its Scientific and Medical Board of Advisors (SAMBA).

AmStem President Dwight Brunoehler said, "Dr. Glantz is a world leader in the field of neuro-oncology and the treatment of brain tumors. He has done important work in the area of stem cell-directed therapies for patients with primary central nervous system malignancies. His expertise will play an important role in helping us to develop our existing intellectual property as well as to develop new strategies for stem cell applications in this area."

Dr. Glantz said, "I am delighted to join Dwight and the members of the impressive scientific and medical board that is being assembled by AmStem. Because of AmStem's powerful stem cell technology and the impressive activity in Korea under the leadership of Dr. Han, the company has an opportunity to become a major player in stem cell treatments for a wide variety of medical problems. I greatly look forward to contributing to that activity."

Dr. Glantz is currently a professor of Neurosurgery, Oncology, and Neurology at Penn State University and the Milton S. Hershey Medical Center. He has published over 90 articles in journals including the Journal of Clinical Oncology, Cancer, Neurology and The Journal of Neuro-Oncology and more than a dozen book chapters. He has given more than a hundred invited presentations at national and international conferences and academic institutions. In addition he also spends time designing clinical trials and teaching evidence-based medicine and statistics to medical and graduate students.

Dr. Glantz graduated Magna Cum Laude from Brown University School of Medicine and has an MD degree from Brown University. He subsequently received medical and neurology training at the State University of New York, oncology and neuro-oncology training at Duke University and epidemiology training at the University of Massachusetts School of Public Health.

His current clinical interests include the diagnosis and treatment of patients with neoplastic meningitis; novel targeted therapies for patients with malignant gliomas and metastatic brain tumors; stem cell-directed therapies for patients with primary central nervous system malignancies; strategies to prevent central nervous system spread of tumor in patients with cancer; the molecular epidemiology of treatment-related toxicity; interventions to prevent chemotherapy-induced nervous system toxicity; and the measurement and preservation of quality of life in cancer patients.

He is a member of American Academy of Neurology, for which he serves as a member of Quality Standards Subcommittee, and Practice Improvement Subcommittee.

About AmStem Corp.

AmStem Corp. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.

An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

For more information contact AmStem President Dwight Brunoehler at (415) 956-2410 or Tom Fox at Hawk Associates at (305) 451-1888 or visit: http://amsteminc.com.

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statement contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statement to reflect events or circumstances that occur after the date hereof.

 

Contact: AmStem Corporation
Dwight Brunoehler, President, 415-956-2410
or
Hawk Associates
Tom Fox, 305-451-1888
http://amsteminc.com

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.